Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited
28 Décembre 2016 - 12:34AM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces that it has
filed a class action lawsuit in the United States District Court
for the Central District of California on behalf of a class (the
“Class”) consisting of persons and entities that purchased or
otherwise acquired Teva Pharmaceutical Industries Limited (“Teva”
or the “Company”) (NYSE: TEVA) securities between February 10,
2014 and November 3, 2016, inclusive (the “Class Period”).
If you are a member of the Class described above, you may move
the Court no later than January 5, 2017, to serve as lead
plaintiff. Please contact Lesley Portnoy at 888-773-9224 or
310-201-9150, or at shareholders@glancylaw.com to discuss this
matter.
On November 3, 2016, Bloomberg published the article “U.S.
Charges in Generic-Drug Probe to Be Filed by Year End” which
discussed the Department of Justice’s two year investigation of
suspected price collusion by several pharmaceutical companies,
including Teva, which will likely result in prosecutors filing
criminal charges by the end of the year.
The complaint filed in this lawsuit alleges that Defendants made
false and/or misleading statements and/or failed to disclose that:
(1) Teva and several of its pharmaceutical industry peers colluded
to fix generic drug prices; (2) the foregoing conduct constituted a
violation of federal antitrust laws; (3) consequently, Teva’s
revenues during the Class Period were in part the result of illegal
conduct; and (4) as a result, Teva’s public statements were
materially false and misleading at all relevant times.
If you purchased shares of Teva during the Class Period you may
move the Court no later than January 5, 2017 to
ask the Court to appoint you as lead plaintiff. To be a member of
the Class you need not take any action at this time; you may retain
counsel of your choice or take no action and remain an absent
member of the Class. If you wish to learn more about this
action, or if you have any questions concerning this announcement
or your rights or interests with respect to these matters, please
contact Lesley Portnoy, Esquire, of Glancy Prongay &
Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, at (310) 201-9150, by e-mail to
shareholders@glancylaw.com, or visit our website
at www.glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161227005274/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024